Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC and a Moderate to High Risk
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 18 May 2018 Status changed from active, no longer recruiting to recruiting.
- 03 Apr 2018 Status changed from not yet recruiting to active, no longer recruiting.